← Back to Search

HPARSS Alert System for Childhood Cancer Survivors

N/A
Recruiting
Led By Robert J Hayashi, M.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Treatment including chemotherapy and/or radiation therapy
Patients with a diagnosis of pediatric cancer (diagnosis at <18 years of age)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 1 year after the completion of screening test for all participants (estimated to be 1 year and 9 months)
Awards & highlights

Study Summary

This trial will try to reduce barriers to prompt screening of sensory deficits in childhood cancer survivors using an electronic alert system.

Who is the study for?
This trial is for childhood cancer survivors aged 7-17, who finished treatment between 6 months and 2 years ago at Washington University School of Medicine. They must speak English and not have had sensory deficit screening or therapy before.Check my eligibility
What is being tested?
The study tests a new system called HPARSS designed to help doctors identify kids at risk of sensory deficits after cancer treatment, prompting timely screening and intervention.See study design
What are the potential side effects?
Since this trial involves screening rather than medication, there are no direct side effects from drugs. However, the process may cause anxiety or discomfort during testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am receiving or have received chemotherapy or radiation therapy.
Select...
I was diagnosed with cancer before turning 18.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 1 year after the completion of screening test for all participants (estimated to be 1 year and 9 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 1 year after the completion of screening test for all participants (estimated to be 1 year and 9 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of at risk patients who fail the assigned screening test
Diagnostic tests
Percentage of patients with at risk for sensory deficits identified by HPARSS
Secondary outcome measures
Acceptability of HPARSS as measured by the Acceptability of Intervention Measure (AIM)
Feasibility of intervention as measured by Feasibility of Intervention Measure (FIM)
Number and types of barriers to participation in formal diagnostic testing and therapy in CCS failing to engage in sensory screening
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS)Experimental Treatment1 Intervention
The primary oncology team will utilize the HPARSS to identify patients who are at risk for sensory deficits based on prior treatment. The HPARSS will constitute a file of that will contain eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study. Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff.
Group II: Providers: Highlighting Patients at Risk for Sensory Screening (HPARSS)Active Control1 Intervention
-Providers will complete a survey regarding their views of the HPARSS. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.

Find a Location

Who is running the clinical trial?

St. Jude Children's Research HospitalOTHER
428 Previous Clinical Trials
5,306,467 Total Patients Enrolled
Washington University School of MedicineLead Sponsor
1,933 Previous Clinical Trials
2,299,579 Total Patients Enrolled
Robert J Hayashi, M.D.Principal InvestigatorWashington University School of Medicine

Media Library

Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS) Clinical Trial Eligibility Overview. Trial Name: NCT05582551 — N/A
Childhood Cancer Research Study Groups: Providers: Highlighting Patients at Risk for Sensory Screening (HPARSS), Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS)
Childhood Cancer Clinical Trial 2023: Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS) Highlights & Side Effects. Trial Name: NCT05582551 — N/A
Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05582551 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must one meet to become a participant in this experiment?

"This clinical trial is enrolling 159 individuals aged between 7 and 17 who are currently battling cancer during childhood. Eligibility requirements include: a diagnosis of pediatric cancer, treatment with chemotherapy or radiation therapy, 6-24 months since completion of all cancer therapies, connection to Washington University School of Medicine's Division for Pediatric Hematology/Oncology Program, current age between 7 and 17 years old (ages where the necessary screenings can be completed by our research team), fluency in English."

Answered by AI

Does this research endeavor permit seniors to participate?

"The minimum age of eligibility for this research is listed as 7 years old, with the maximum age set at 17."

Answered by AI

Are there any openings for volunteers in this investigation?

"Presently, the clinical trial detailed on clinicialtrials.gov is not looking for participants; initiated December 31st 2022 and last updated October 17th 2022. Nevertheless, there are 24 other studies recruiting individuals at this time."

Answered by AI

Who else is applying?

What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
2023. "Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05582551.
All > Vision > Peripheral Neuropathy
~90 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top